Composition

Abstract

Provided is a composition comprising Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii, the Chlamydomonas reinhardtii or the extract of Chlamydomonas reinhardtii comprising an antagonist of a histamine receptor.

Description

Technical Field

[0001] The present invention relates to a composition comprising Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii. Background Art

[0002] Drug development is ongoing to ensure healthy living and promote well-being for all people of all ages.

[0003] Patent Document 1 describes a pharmaceutical composition containing a wound-healing substance. Here, the wound-healing substance is selected from the group consisting of vitamins or provitamins, carotenoids, analgesics, disinfectants, hemostatics, antihistamines, antimicrobial metals or salts thereof, plant-derived wound-healing substances or substance mixtures, plant extracts, enzymes, growth factors, enzyme inhibitors, and combinations thereof.

[0004] On the other hand, Patent Document 2 describes the Honda DREAMO strain (Deposit No. FERM BP-22306) as an example of Chlamydomonas reinhardtii.

[0005] [Prior Art Literature]

[0006] (Patent Document)

[0007] Patent Document 1: Japanese Patent Application No. 2009-519917

[0008] Patent Document 2: International Publication No. 2017 / 217116 Summary of the Invention

[0009] [Problems to be solved by the invention]

[0010] However, it is not known that Chlamydomonas reinhardtii or extracts of Chlamydomonas reinhardtii function as histamine receptor antagonists.

[0011] An object of the present invention is to provide a composition comprising, as an active ingredient, Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii that functions as a histamine receptor antagonist.

[0012] [Technical means to solve the problem]

[0013] (1) A composition comprising Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii, wherein the Chlamydomonas reinhardtii or the extract of Chlamydomonas reinhardtii contains an antagonist of a histamine receptor.

[0014] (2) The composition according to (1), wherein the Chlamydomonas reinhardtii is the Honda DREAMO strain (Deposit No. FERMBP-22306).

[0015] (3) The composition according to (1) or (2), which is a drug for treating peptic ulcers, a drug for treating reflux esophagitis, a drug for treating upper gastrointestinal bleeding, or a drug for treating gastric mucosal lesions.

[0016] (4) The composition according to any one of (1) to (3), wherein the histamine receptor is histamine receptor H2.

[0017] (5) The composition according to any one of (1) to (4), wherein the Chlamydomonas reinhardtii is a freshwater alga.

[0018] (Effects of the Invention)

[0019] According to the present invention, there is provided a composition comprising, as an active ingredient, Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii that functions as an antagonist of a histamine receptor. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] none DETAILED DESCRIPTION

[0021] Hereinafter, embodiments of the present invention will be described.

[0022] The composition of this embodiment contains Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii, and Chlamydomonas reinhardtii or the extract of Chlamydomonas reinhardtii contains a histamine receptor antagonist.

[0023] Chlamydomonas reinhardtii is not particularly limited, and examples thereof include UTEX 90 strain and Honda DREAMO strain (Deposit No. FERM BP-22306). UTEX 90 strain is the source strain of Honda DREAMO strain.

[0024] Chlamydomonas reinhardtii is preferably a freshwater algae, so that it can be cultivated in large quantities on land.

[0025] Examples of the histamine receptor include histamine receptor H1, histamine receptor H2, histamine receptor H3, and histamine receptor H4. Among these, histamine receptor H2 is preferred.

[0026] The composition of this embodiment contains Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii as an active ingredient, which functions as a histamine receptor antagonist. Therefore, it can be used in pharmaceuticals such as peptic ulcer treatments, reflux esophagitis treatments, upper gastrointestinal bleeding treatments, and gastric mucosal lesion treatments. Examples of peptic ulcers include gastric ulcers, duodenal ulcers, anastomotic ulcers, and Zollinger-Ellison syndrome. Furthermore, examples of gastric mucosal lesions include acute gastric mucosal lesions and chronic gastric mucosal lesions.

[0027] The drug can be administered orally (for internal use) or parenterally (for external use, injection).

[0028] The dosage form of the drug is not particularly limited, and examples thereof include solid preparations such as tablets, granules, powders, and capsules; liquid preparations such as solutions, suspensions, and emulsions; and lyophilized preparations.

[0029] The drug can be produced using known methods.

[0030] The composition of this embodiment can also be used as, for example, quasi-drugs, cosmetics, and foods.

[0031] The composition of this embodiment is preferably used for humans, but can also be used for animals other than humans.

[0032] The method for culturing Chlamydomonas reinhardtii is not particularly limited, and examples thereof include static culture, shaking culture, submerged culture, and aeration culture.

[0033] Chlamydomonas reinhardtii can be cultivated outdoors for large-scale cultivation on land. There are no particular limitations on the method for culturing Chlamydomonas reinhardtii outdoors, and examples include methods using a raceway-type bioreactor in an open pond format and methods using a flat-plate photobioreactor installed outdoors.

[0034] The culture medium used for culturing Chlamydomonas reinhardtii is not particularly limited, and examples thereof include TAP medium, urea medium, HSM medium, and BG11 medium.

[0035] The temperature during the culture of Chlamydomonas reinhardtii is not particularly limited, but is, for example, 2°C or higher and 38°C or lower.

[0036] The light-dark cycle during culturing Chlamydomonas reinhardtii is not particularly limited, and is, for example, a 24-hour cycle in which the light period is 6 hours or more and 24 hours or less.

[0037] The photosynthetically active photon flux density during the bright period is not particularly limited, but is, for example, 50 μmol / m 2 / s and above and 2000 μmol / m 2 / s or less.

[0038] The gas aeration rate per unit volume when culturing Chlamydomonas reinhardtii by the aeration culture method is not particularly limited, and is, for example, 0.001 VVM or more and 10 VVM or less. VVM indicates how many times the volume ratio of gas is aerated into the culture medium per minute.

[0039] When culturing Chlamydomonas reinhardtii using an aeration culture method, carbon dioxide is preferably supplied to the culture medium. The concentration of carbon dioxide in the introduced gas is not particularly limited, and for example, is 0.1% by volume or higher and 10% by volume or lower. Furthermore, the source of carbon dioxide is not particularly limited, and examples thereof include gas discharged from carbon dioxide cylinders, factories, and the like, and concentrated carbon dioxide recovered from the atmosphere using direct air capture (DAC).

[0040] The method for recovering the cultured Chlamydomonas reinhardtii is not particularly limited, and examples thereof include centrifugation and filtration.

[0041] Furthermore, the recovered Chlamydomonas reinhardtii may be dried as needed.

[0042] The method for drying Chlamydomonas reinhardtii is not particularly limited, and examples thereof include freeze drying, spray drying, warm air drying, and sun drying.

[0043] The extraction method for extracting Chlamydomonas reinhardtii is not particularly limited, and examples thereof include ultrasonic extraction.

[0044] The solvent used for extracting Chlamydomonas reinhardtii is not particularly limited. Examples include lower alcohols such as methanol, ethanol, propanol, and isopropanol; lower aliphatic ketones such as acetone and methyl ethyl ketone; polyols such as 1,3-butanediol, propylene glycol, and glycerol; and hydrophilic organic solvents such as dimethyl sulfoxide (DMSO). Among these, DMSO is preferred.

[0045] The method for recovering the Chlamydomonas reinhardtii extract is not particularly limited, and examples thereof include centrifugation and filtration.

[0046] Furthermore, the recovered Chlamydomonas reinhardtii extract may be dried as needed.

[0047] The method for drying the Chlamydomonas reinhardtii extract is not particularly limited, and examples thereof include freeze-drying.

[0048] Example

[0049] Hereinafter, examples of the present invention will be described, but the present invention is not limited to the examples.

[0050] (Example 1)

[0051] [Cultivation of Chlamydomonas reinhardtii]

[0052] Chlamydomonas reinhardtii strain Honda DREAMO was statically cultured using 2 L of TAP medium under the following culture conditions for five days (seed culture).

[0053] Temperature: 25℃

[0054] Light-dark cycle: 12 hours light period, 12 hours dark period

[0055] Photosynthetically active photon flux density during the bright period: 60-80 μmol / m 2 / s

[0056] Light source: White light-emitting diode (LED)

[0057] Next, 500 mL of the seed culture was centrifuged at 3000 rpm for 5 minutes, and then the culture supernatant was removed to recover the seed-cultured Honda DREAMO strain.

[0058] Next, the recovered HondaDREAMO strain was statically cultured for 7 days using 2 L of TAP medium under the same culture conditions as for the seed culture (preculture).

[0059] Next, the pre-cultured HondaDREAMO strain was aerated in 5 L of urea medium under the same culture conditions as the seed culture for 7 days (main culture). The aeration conditions were as follows.

[0060] Gas ventilation per unit volume: 0.15 VVM

[0061] Carbon dioxide concentration in gas: 5% by volume

[0062] Next, 5 L of the main culture was centrifuged at 6000 rpm for 10 minutes, and then the culture supernatant was removed to recover the Honda DREAMO strain after the main culture.

[0063] [extract]

[0064] About 20 mL of the recovered Honda DREAMO strain was subjected to ultrasonic extraction with 100 mL of DMSO for 5 minutes using an ultrasonic homogenizer. The ultrasonic extraction was performed on ice.

[0065] Next, the mixture of the extract and the residue was centrifuged at 3000 rpm for 5 minutes, and then the residue was removed to recover about 100 mL of the extract.

[0066] Next, the extract was freeze-dried to obtain 490.74 mg of an extract of the Honda DREAMO strain.

[0067] [Sample production]

[0068] 490 mg of the Honda DREAMO strain extract was dissolved in 4.9 mL of DMSO using an ultrasonic homogenizer to obtain a 100 mg / mL DMSO solution of the Honda DREAMO strain extract.

[0069] Next, the DMSO solution of the Honda DREAMO strain extract was centrifuged at 15,000 rpm for 5 seconds, and the supernatant was recovered to obtain a sample.

[0070] Next, the following two tests were performed to determine the concentration of samples used in assays (in vitro functional evaluation tests).

[0071] [Cell proliferation inhibition test]

[0072] A dose-dependent study was conducted using samples added to HEK293 cells (a cell line derived from human embryonic kidney cells) cultured in D-MEM (high glucose) + 10% fetal bovine serum (FBS) + 1% penicillin-streptomycin. Samples were added at 13 concentrations (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 250, and 500 μg / mL). Twenty-four hours after sample addition, the medium was replaced and the cells were stained with WST-8 for four hours. Optical density (OD) was then measured at a wavelength of 450 nm using a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices). This experiment was conducted with n = 3 participants.

[0073] As a result, no decrease in optical density was observed at any sample concentration, and thus it was determined that there was no influence due to concentration.

[0074] [Influence of sample on optical density]

[0075] Samples were added to D-MEM (High Glucose) + 10% FBS + 1% Penicillin-Streptomycin medium at 13 concentrations (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 250, and 500 μg / mL) 24 hours later. The medium was replaced and staining with WST-8 was performed for 4 hours. Optical density at a wavelength of 450 nm was then measured using a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices). This experiment was performed with n = 3 participants.

[0076] The results showed an increase in optical density at sample concentrations of 250 μg / mL and 500 μg / mL. Therefore, it was found that adding sample at concentrations of 250 μg / mL and 500 μg / mL affected the optical density regardless of the cells. On the other hand, adding sample at concentrations of 100 μg / mL or less did not affect the optical density.

[0077] Based on the above results, the maximum concentration of 100 μg / mL, at which no inhibition of cell growth or influence of the sample on optical density was observed, was set as the sample concentration used in the assay.

[0078] [assay]

[0079] The assay was conducted using samples targeting the histamine receptor H2 at a concentration of 100 μg / mL. The assay was repeated twice. The assay was outsourced to Eurofins Pharma Discovery Services, and two assay systems were used to exclude suspected positives. Target molecules with an inhibition rate of 50% or greater were considered to have antagonistic activity.

[0080] Table 1 shows the test results of the samples.

[0081] [Table 1]

[0082] target molecule effect Inhibition rate [%] The efficacy of drugs targeting target molecules <![CDATA[Histamine receptor H2]]> antagonists 54 Drugs for treating peptic ulcers, reflux esophagitis, upper gastrointestinal bleeding, and gastric mucosal lesions

[0083] As shown in Table 1, the extract of the Honda DREAMO strain contained in the sample contains an antagonist of the histamine receptor H2, that is, it functions as an antagonist of the histamine receptor H2.

Claims

1. A composition comprising Chlamydomonas reinhardtii or an extract of Chlamydomonas reinhardtii, The Chlamydomonas reinhardtii or the extract of the Chlamydomonas reinhardtii contains an antagonist of histamine receptors.

2. The composition according to claim 1, wherein The aforementioned Chlamydomonas reinhardtii is the Honda DREAMO strain (Deposit No. FERM BP-22306).

3. The composition according to claim 1 or 2, which is a therapeutic agent for peptic ulcer, a therapeutic agent for reflux esophagitis, a therapeutic agent for upper gastrointestinal bleeding, or a therapeutic agent for gastric mucosal lesions.

4. The composition according to claim 1 or 2, wherein The aforementioned histamine receptor is histamine receptor H2.

5. The composition according to claim 1 or 2, wherein The aforementioned Chlamydomonas reinhardtii is a freshwater algae.